Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF2BP2 | Q9Y6M1 | 1/20 | 0.58 |
| ▸ | ABL1 | P00519 | 6/20 | 0.52 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | ACLY | P53396 | 2/20 | 0.50 |
| ▸ | DHODH | Q02127 | 6/20 | 0.47 |
| ▸ | KDM5A | P29375 | 1/20 | 0.47 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.47 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.47 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.46 |
| ▸ | KCNK10 | P57789 | 1/20 | 0.46 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1317574 | 0.91 | DHODH (0.52) | IGF2BP2ABL1SCN10AOPRM1KCNH2 | |
| SCHEMBL1318104 | 0.89 | ACLY (0.50) | IGF2BP2ACLYDHODHSUCNR1 | |
| SCHEMBL1315613 | 0.87 | HDAC2 (0.56) | ACLYDHODHSUCNR1 | |
| SCHEMBL2276941 | 0.87 | IGF2BP2 (0.68) | IGF2BP2ACLYDHODHKCNK2KCNK10 | |
| SCHEMBL1316613 | 0.86 | SCN10A (0.49) | IGF2BP2ABL1SCN10AOPRM1KCNH2 | |
| SCHEMBL1315751 | 0.85 | ACLY (0.64) | ACLYDHODHKDM4CSUCNR1 | |
| SCHEMBL1319354 | 0.85 | RXRA (0.54) | ACLYDHODHSUCNR1 | |
| SCHEMBL1316878 | 0.85 | ACLY (0.60) | ACLYSUCNR1 | |
| SCHEMBL1317101 | 0.84 | ACLY (0.51) | IGF2BP2ABL1SCN10AOPRM1KCNH2 | |
| SCHEMBL15127677 | 0.83 | ACLY (0.52) | IGF2BP2ABL1SCN10AOPRM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492582-B2 | N-acyl anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-07-23 | — | — | US | disclosed |
| US-20110275797-A1 | N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-11-10 | — | — | US | disclosed |
| EP-2385036-A1 | N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | Toyama Chemical Co., Ltd. (JP) | 2011-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275797-A1 | N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | COL14A1, COL2A1, COL1A1 | IGF2BP2 3771/4885ABL1 849/4885SCN10A 820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.